Guidance Maintaining an Adequate Supply of Chronic Prescription Medication during the COVID-19 Pandemic
This article was archived from the previous WordPress site. Formatting and media should be close, but may not match the original post perfectly.
| The Food and Drug Administration (FDA) has been closely monitoring the medical supply chain in the United States during the COVID-19 pandemic, understanding that it may be impacted, potentially leading to supply disruptions or shortages.
The Department of Consumer Protection’s (DCP) Drug Control Division has been monitoring FDA actions, and cares deeply about the significant impact that this pandemic may have on patient care. The FDA and DCP are doing everything within their authority to help prevent and alleviate shortages. They continue to work with manufacturers, pharmacies, and direct care facilities to reduce and prevent shortages as the COVID-19 situation evolves. Any medication shortages, including any related to COVID-19, will be posted on the FDA Drug Shortages webpage. |